Zurück zu Projekte

16771.3 PFLS-LS

Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test

Zusammenfassung

Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test

Weitere Texte

Abstract

The goal of the interdisciplinary ProteoMediX/ETHZ/USZ/FHNW project is to develop an immunoassay-based risk stratification test (PMX-Px) for the prognosis of patients diagnosed|with localized prostate cancer (PCa) by using Mass Spectrometry-GUided Immunoassay DEvelopment (MS-GUIDE). A commercially available kit in the context of personalized|medicine will provide doctors and patients with a tool supporting them in their decision making in between prostatectomy or active surveillance for patients with localized|PCa.

Beteiligte

Bernd Wollscheid

Kontaktperson

wbernd@ethz.ch

ETH Zürich Bernd Wollscheid Auguste-Piccard-Hof 1 8093 Zürich ZH CH

Ralph Schiess

Wirtschaftspartner

schiess@proteomedix.com

ProteoMediX AG Ralph Schiess Wagistrasse 23 8952 Schlieren ZH CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2015-03-31
Enddatum
2017-12-31
Bewilligte Gesamtkosten
CHF 738810.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%